Skip to main content
Clinical Trials/JPRN-C000000370
JPRN-C000000370
Completed
未知

Multicenter study for the effect preserving renal function of HMG-CoA reductase inhibitor (simvastatin) in type 2 diabetic nephropathy with hyperlipidemia (MIDN Study) - Multicenter study for the effect preserving renal function of HMG-CoA reductase inhibitor in type 2 diabetic nephropathy (MIDN Study)

Japanese Society of Kidney and Lipids0 sites200 target enrollmentMarch 27, 2006

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Japanese Society of Kidney and Lipids
Enrollment
200
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 27, 2006
End Date
December 1, 2007
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japanese Society of Kidney and Lipids

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Type 1 diabetes mellitus. 2\) The subject has cardio\-vascular complications as follows: receiving coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within 3 months; unstable angina; myocardial infarction; transient ischemic attack (TIA) within 6 months, congestive heart failure classified into class III or IV of New York Heart Association (NYHA); cerebral infarction within 3months. 3\) The subject has non diabetic nephropathy such as chronic glomerulonephritis, nephrotic syndrome and polycystic kidney. 4\) The subject's serum creatinine is more than 2\.5mg/dL. 5\) The subject has secondary hypertension except that due to diabetes. 6\) The subject's HbA1c is more than 9%. 7\) The subject is inappropriate for participation in the study for other reasons, as determined by an investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials